PD-L1 and Immunotherapy in Patients with Non-Small Cell Lung Cancer and Malignant Pleural Effusion

: Immunotherapy has emerged as a potent tool in the treatment of lung cancer, particularly in patients with advanced disease. Multiple drugs are now available which cause an anti-tumor immune response by blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, which is expressed in some tumors. This review explores the role of immunotherapy and the practi-cal implications of testing for PD-L1 in patients with malignant pleural effusion.

[1]  J. Juco,et al.  Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.

[2]  M. Berger,et al.  NEXT GENERATION SEQUENCING OF UROTHELIAL BLADDER CANCER: MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE IN 454 PATIENTS: MP54‐04 , 2018 .

[3]  Benjamin Solomon,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  B. Sundaram,et al.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecula , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Heymann,et al.  PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens , 2017, Cancer cytopathology.

[6]  B. Skov,et al.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  A. Borczuk,et al.  Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. , 2017, Archives of pathology & laboratory medicine.

[8]  H. Rugo,et al.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Taube,et al.  Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC , 2017, Cancer immunology research.

[10]  D. Rimm,et al.  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.

[11]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[12]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[13]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[14]  S. Steinberg,et al.  Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  W. Bulman,et al.  Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. , 2016, Clinical lung cancer.

[16]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[17]  M. Ladanyi,et al.  Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience. , 2016, Archives of pathology & laboratory medicine.

[18]  S. Roy-Chowdhuri,et al.  Preanalytic Variables in Cytology: Lessons Learned From Next-Generation Sequencing-The MD Anderson Experience. , 2016, Archives of pathology & laboratory medicine.

[19]  E. Felip,et al.  Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). , 2016, Lung cancer.

[20]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[21]  Marius Ilie,et al.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients , 2016, Virchows Archiv.

[22]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[23]  B. S. Andrews,et al.  The role of immune complexes in the pathogenesis of pleural effusions. , 2015, The American review of respiratory disease.

[24]  A. Saqi,et al.  FNA, core biopsy, or both for the diagnosis of lung carcinoma: Obtaining sufficient tissue for a specific diagnosis and molecular testing , 2015, Cancer cytopathology.

[25]  M. Krasnik,et al.  The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[26]  Brennan C Kahan,et al.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score , 2014, Thorax.

[27]  R. Maxfield,et al.  Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples , 2014, CytoJournal.

[28]  L. de Esteban Júlvez,et al.  Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors. , 2014, Lung cancer.

[29]  M. Wahidi,et al.  Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[30]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[31]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[32]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[33]  J. Kwiatkowski.  Real-world use of iron chelators. , 2011, Hematology. American Society of Hematology. Education Program.

[34]  Gregg Staerkel,et al.  EGFR and KRAS mutations in lung carcinoma , 2011, Cancer cytopathology.

[35]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  J. Pollak,et al.  Management of Malignant Pleural Effusions , 2008, Seminars in respiratory and critical care medicine.

[37]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[38]  J. M. Porcel,et al.  Rentabilidad del estudio citológico del líquido pleural en el derrame maligno , 2008 .

[39]  T. Morgenthaler,et al.  Sonographically guided thoracentesis and rate of pneumothorax , 2005, Journal of clinical ultrasound : JCU.

[40]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Goldstraw,et al.  Management of malignant pleural effusions. , 2001, The European respiratory journal.

[42]  F. Rodríguez‐Panadero,et al.  Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. , 1989, The European respiratory journal.

[43]  C. Hsu,et al.  Cytologic detection of malignancy in pleural effusion: A review of 5,255 samples from 3,811 patients , 1987, Diagnostic cytopathology.

[44]  S. Sahn,et al.  Carcinomatous involvement of the pleura: an analysis of 96 patients. , 1977, The American journal of medicine.

[45]  Dines De,et al.  The value of cells in the pleural fluid in the differential diagnosis. , 1975 .

[46]  M. Schwarz,et al.  Hodgkin's disease of the lung. , 1972, The American review of respiratory disease.

[47]  M. Melamed.  The cytological presentation of malignant lymphomas and related diseases in effusions , 1963, Cancer.

[48]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[49]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[50]  日野 亮介.  Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma , 2010 .

[51]  C. Toh.  The changing epidemiology of lung cancer. , 2009, Methods in molecular biology.

[52]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[53]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[54]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[55]  D. E. Dines,et al.  The value of cells in the pleural fluid in the differential diagnosis. , 1975, Mayo Clinic proceedings.